Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

SABS stock hub

SAB Biotherapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

SABSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

288.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

SABS

In the news

Latest news · SABS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/E67.8

P25 14.9P50 23.2P75 38.5

ROE15

P25 -105.6P50 -46.5P75 -3.1

ROIC-32.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All SABS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

189

Groups with data

Currency

USD

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001833214
Company name	SAB Biotherapeutics, Inc.
Country	United States
Country code	US
Cusip	78397T103
Employees	86
Employees Change	23%
Employees Change Percent	36.51
Enterprise value	$198.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US78397T2024
Last refreshed	2026-05-10
Market cap	$288.8M
Market cap category	Micro-Cap
Price	$4.11
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	SABS
Website	https://www.sab.bio

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.48%
EV Earnings	46.51x
FCF yield	-15.83%
P/B ratio	1.29x
P/E ratio	67.78x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-33.4M
Net Income	$4.3M
Net Income Growth Years	2%
Net Income Growth5 Y	-26.69%
Profit Per Employee	$49,550
Profitable Years	1
ROA	-28.2
Roa5y	-28.98
ROCE	-30.19
ROE	14.96
Roe5y	-52.1
ROIC	-32.53

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	143.33%
Cagr3y	-22.08%
Cagr5y	-47.09%
EPS Growth Quarters	2
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$172.8M
Cash	$96.6M
Current Assets	$101.1M
Current Liabilities	$10.7M
Debt	$6M
Debt Equity	$0.04
Equity	$151.5M
Interest Coverage	-203.4
Liabilities	$21.3M
Long Term Assets	$71.8M
Long Term Liabilities	$10.6M
Net Cash	$90.6M
Net Cash By Market Cap	$31.38
Net Cash Growth	463.28%
Net Debt Equity	$-0.6
Tangible Book Value	$151.5M
Tangible Book Value Per Share	$3.18
WACC	7.27

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.46
Net Working Capital	$-5.3M
Quick ratio	9.13
Working Capital	$90.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-562.28%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	143.18%
200-day SMA	3.31
3Y total return	-52.7%
50-day SMA	3.87
50-day SMA vs 200-day SMA	50over200
5Y total return	-95.85%
All Time High	129
All Time High Change	-96.81%
All Time High Date	2021-10-22
All Time Low	1
All Time Low Change	311%
All Time Low Date	2025-04-04
ATR	0.31
Beta	0.56
Beta1y	-0.12
Beta2y	0.81
Ch YTD	9.89
High	4.59
High52	6.6
High52 Date	2025-07-21
High52ch	-37.73%
Low	3.79
Low52	1.6
Low52 Date	2025-06-13
Low52ch	156.88%
Ma50ch	6.31%
Premarket Change Percent	1.35
Premarket Price	$4.15
Premarket Volume	26,647
Price vs 200-day SMA	24.13%
RSI	59.41
RSI Monthly	39.92
RSI Weekly	57.48
Sharpe ratio	1.42x
Sortino ratio	2.55
Total Return	-562.28%
Tr YTD	9.89
Tr1m	9.31%
Tr1w	18.44%
Tr3m	-1.44%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$15
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.21
Operating Income	$-49M
Price target	$10.75
Price Target Change	$162
Price Target Change Top	$265

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	48,107,050%
Float Percent	68.45%
Net Borrowing	-418,412
Shares Insiders	2.69%
Shares Institutions	32.24%
Shares Out	70,275,714
Shares Qo Q	-38.36%
Shares Yo Y	562.28%
Short Float	6.24%
Short Ratio	4.51
Short Shares	4.27

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-50.9M
Average Volume	854,818.95x
Bv Per Share	3.18
CAPEX	$-933,156
Ch1m	9.31
Ch1w	18.44
Ch1y	143.2
Ch3m	-1.44
Ch3y	-52.7
Ch5y	-95.85
Ch6m	28.44
Change	0.49%
Change From Open	-1.67
Close	4.09
Days Gap	2.2
Depreciation Amortization	3,081,586
Dollar Volume	24,773,600.4
Earnings Date	2026-05-12
Earnings Time	bmo
EBIT	$-49M
EBITDA	$-45.9M
EPS	$-0.79
F Score	2
FCF	$-45.7M
FCF EV Yield	-23.06x
FCF Per Share	$-0.65
Financing CF	168,299,452
Fiscal Year End	December
Founded	2,014
Investing CF	-121,706,130
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-09
Last Report Date	2025-12-31
Last Split Date	2024-01-05
Last Split Type	Reverse
Last10k Filing Date	2026-03-09
Ma150	3.68
Ma150ch	11.65%
Ma20	3.78
Ma20ch	8.7%
Net CF	1,604,714
Next Earnings Date	2026-05-12
Open	4.18
Optionable	Yes
Position In Range	39.9
Post Close	4.11
Postmarket Change Percent	5.59
Postmarket Price	$4.34
Ppne	19,404,973
Pre Close	4.09
Price Date	2026-05-08
Ptbv Ratio	1.91
Relative Volume	7.05x
Share Based Comp	5,210,647
Tr6m	28.44%
Us State	Florida
Volume	6,027,640

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does SABS pay a dividend?

Capital-return profile for this ticker.

Performance

SABS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns SABS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+32.2%

Float: +68.5% of shares outstanding

Insider ownership

+2.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

SABS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.4

Neutral momentum band

Price vs 200-day MA

+24.1%

50/200-day relationship not available

Beta (5Y)

0.56

Less volatile than the market

Sharpe ratio

1.42

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About SABS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current SABS stock rating?

SAB Biotherapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SABS analysis?

The full report lives at /stocks/SABS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for SABS?

The latest report frames SABS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the SABS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.